1402 (1402) Fair Value & Analysis

Technology · Market cap HK$268M

1 1402 1402 · HK

PriceHK$0.2220

Fair ValueHK$0.0400

Upside-82.0%

Quality61/100

Evidence: High Range HK$0.0400 – HK$0.0400

Fair value as of: Jul 2, 2026

From 22 valuation models · updated today

Share price −19.3% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.1690 – HK$0.3300 · the HK$0.2220 price screens above the HK$0.0400 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1402 (1402) currently trades at HK$0.2220, while our model-based Fair Value estimate is HK$0.0400 — implying the stock looks roughly 82.0% overvalued today. We read business quality at 61/100 (solid quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1402 generated revenue of HK$105M at a net margin of 0.4%. Revenue grew 0.1% year over year. It earns a return on equity of 0.3%. The balance sheet holds a net cash position of HK$40.2M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$105M

Revenue growth (YoY) +0.1%

Net margin 0.4%

Return on equity 0.3%

Free cash flow HK$17.9M FY2025

Operating margin 0.3%

More key figures

EPS growth (YoY) -8.4%

Net cash HK$40.2M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

1402 reported revenue of HK$105M in FY2026 versus HK$171M in FY2022, a compound −11.5%/yr. Reported net income was HK$367K in FY2026, compounding −51.6%/yr from FY2022.

Revenue −11.5%/yr

FY22 HK$171M

FY23 HK$158M

FY24 HK$122M

FY25 HK$122M

FY26 HK$105M

Net income −51.6%/yr

FY22 HK$6.7M

FY23 HK$5.7M

FY24 −HK$12.9M

FY25 −HK$18.3M

FY26 HK$367K

Is 1402 fairly valued? → Check now

Similar stocks

6 more Information Technology Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
International Business Machines Corporation IBM	$272.36	$174.70	-36%
Accenture plc ACN	$178.86	$228.49	+28%
Tata Consultancy Services Limited TCS	₹2,199	₹1,863	-15%
Infosys Limited INFY	₹1,065	₹15.23	-99%
Fujitsu Limited FJTSF	$19.70	$17.37	-12%
HCL Technologies Limited HCLTECH	₹1,155	₹1,220	+6%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1402 (1402) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0400 versus a price of HK$0.2220 — about −82% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1402?

Our model-based fair value for 1402 is HK$0.0400 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2220.

What is the quality score of 1402?

1402 has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1402 (1402)?

1402 reported trailing-twelve-month revenue of about HK$105M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1402?

The net profit margin of 1402 is about 0.4%, meaning it keeps roughly 0.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.